Image Credit: Presidio Medical
Presidio Medical is a San Francisco-based private company founded in 2017 to develop neuromodulation devices based on the delivery of ultra-low frequency (ULF) signals.
The idea is to use very low frequency biphasic currents to achieve the same type of blocking effect that DC Direct current has on the propagation of nerve action potentials, but without damaging tissues.
A paper published in Science in 2021 on Presidio-sponsored studies conducted with ULF signals showed that a ULF waveforms produced a rapidly-developing and completely reversible conduction block in animal models. The same paper reported on a 2-week human trial that tested the analgesic effects of epidural ULF currents in 20 subjects with chronic leg and back pain. Pain ratings improved by 90% after 2 weeks and returned to 72% one week after lead explant.
In June 2023, Presidio announced that it had received $72 million Series C funding round led by Deerfield Management, existing investors Invus Opportunities and Action Potential Venture Capital, and joined by ShangBay Capital. Presidio is using these funds to expand their team, scale manufacturing, and conduct long-term, pivotal clinical studies of the ULF™ SCS system.
Neuros Medical received an Investigational Device Exemption to conduct a pivotal clinical trial to evaluate the Altius™ System High Frequency Nerve Block technology for the management of intractable limb pain of amputees. The prospective, randomized, controlled pivotal clinical trial will consist of 130 patients at 15 institutions in the U.S. to evaluate the safety and efficacy of Neuros Medical’s Altius System.
